Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone PCA titration followed by conversion to Rui Anning oxycodone extended-release for moderate to severe cancer pain
ChiCTR2400080661Phase 4Not yet recruiting
- Sponsor
- The First College of Clinical Medical Science, China Three Gorges University
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydromorphone and oxycodone in cancer pain, sponsored by The First College of Clinical Medical Science, China Three Gorges University. Primary endpoint: Conversion success rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
hydromorphoneoxycodone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2400080661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080661.